Microbot Medical appointed Alon Tamir as VP of Sales for EMEA to accelerate international commercial readiness, leveraging its FDA-cleared LIBERTY system and targeting CE mark approval by end of 2026.
Key takeaways
Alon Tamir appointed VP of Sales, EMEA, bringing over 20 years of medtech experience to lead international expansion.
Company prioritizing U.S. market while building regulatory and commercial capabilities for EMEA entry.
LIBERTY system FDA-cleared (Sept 2025) and commercially launched; CE mark expected by end of 2026.
Europe represents ~2.3 million peripheral endovascular procedures annually, comparable to U.S. market.
International strategy includes leveraging FDA clearance and pursuing CE mark to accelerate market access.
Appointment supports distribution partnerships and tailored product launches ahead of regulatory approvals.